focus -WSS

focus

author：Wikipedia 2025-10-01 15:30:44 - browse：48

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Readout Newsletter: Beam, Prozac, "TechBio" and more

WSS

Senators: Long

CDC panel: People 65 and older should get a Covid spring booster shot

Redefining sustainability for the pharmaceutical industry

'Vaccine

Neuroscience renaissance leads to new crop of psychiatric drugs

Redefining sustainability for the pharmaceutical industry

explore

focus

focus

BioMarin wins approval for gene therapy to treat hemophilia A

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

How one medical school became remarkably diverse

Biotech lab space demand falls sharply

Peter Hotez and the public health issue of online harassment

Ohio train derailment: Experts on toxic chemical risks

Sports medicine is finally prioritizing gender equality

Study fuels hope CAR

United colonoscopy coverage change 'may cost lives,' doctors say

Neuroscience renaissance leads to new crop of psychiatric drugs

explore

Medicare Advantage isn’t working — for anyone

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Cholera vaccine supplies dangerously low, outbreaks surging

How AI helped researchers track recovery from depression

Biotech stock slump in 2023: awaiting the turnaround

Hearing on Medicare drug price negotiation gets unusually heated

focus

focus

Wikipedia

focus